Thursday, February 12, 2015; 3:00 PM - 5:00 PM
Section outline
-
Lecture:Â Evidence Based Medicine, Meta-Analysis, Case Studies
Evidence-based medicine: the state of the art
- Understand the genesis of evidence based medicine
- Understand the use and application of ‘meta-analyses’ and ‘systematic reviews’ in the generation of evidence based medicine
- Explore the value of meta analysis in regulatory decision making: the Vioxx example
- Case Study: Effect Measure Selection in MetaAnalysis – A Case study from Pharmacoepidemiology
Faculty:Â Michael Kelsh/ F. Callaghan
Location:Â Mission Hall 1407
-
Guyatt et al., Users’ Guides to the Medical Literature XXV. Evidence-Based Medicine. Principles for Applying the Users’ Guides to Patient Care. JAMA 284(10)-1290-1296, 2000 File
-
Concato et al., Randomized, Controlled Trials, Observational Studies, and the Hierarchy Of Research Designs. N Engl J Med 342(25) 1887-92, 2000 File
-
Juni et al., Risk of cardiovascular events and rofecoxib. cumulative meta-analysis. Lancet 364(9450) 2021-2029, 2004 File
-
Poole 2007 Coffee and Myocardial Infarction. File
-
New RAS-Mutant Pancreatic Adenocarcinoma With Combined BRAF and MEK Inhibition for Metastatic Melanoma File
-
Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes File
-
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma File
-
Caterson et al. - 2012 - Maintained intentional weight loss reduces cardiov File
-
James et al. - 2010 - Effect of Sibutramine on Cardiovascular Outcomes i File
-
Vemurafenib in patients with BRAFV600 mutated metastatic melanoma: an open-label, multicentre, safety study File
-
RECORD RosiglitazoneRosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial File
-
Progression of RAS-Mutant Leukemia during RAF Inhibitor Treatment File